Genmab | GEN - Current Assets


Genmab reported DKK2.88B in Current Assets for its fiscal quarter ending in December of 2025.





Current Assets Change Date
Agios Pharmaceuticals USD 717.67M 117.18M Jun/2026
Almirall EUR 747.1M 33.12M Jun/2026
Amarin USD 602.76M 23.26M Jun/2026
Amgen USD 34.96B 3.49B Jun/2026
argenx SE USD 8.07B 1.17B Jun/2026
AstraZeneca USD 27.97B 1.65B Jun/2026
Bayer EUR 35.3B 2.39B Mar/2026
BioMarin Pharmaceutical USD 4.61B 651.58M Mar/2026
Demant DKK 10.08B 128M Dec/2025
Exelixis USD 1.21B 234.65M Mar/2026
Fresenius Medical Care EUR 8.11B 209.55M Mar/2026
Genmab DKK 2.88B 1.59B Dec/2025
GlaxoSmithKline GBP 17.56B 202M Jun/2026
GN Store Nord DKK 4.85B 3.79B Mar/2026
GRIFOLS EUR 5.31B 51M Jun/2026
Hikma Pharmaceutical USD 2.64B 86M Dec/2025
Insmed USD 1.61B 181.04M Mar/2026
Lakefront Biotherapeutics EUR 3.06B 18.72M Mar/2026
Lonza CHF 8B 3.41B Dec/2025
Merck EUR 14.16B 932M Mar/2026
Novartis USD 27.35B 744M Jun/2026
Regeneron Pharmaceuticals USD 18.45B 236.8M Jun/2026
Roche Holding CHF 35.44B 3.29B Jun/2026
Sanofi EUR 31.52B 1.36B Jun/2026
UCB EUR 6.05B 733M Dec/2025